A registration-directed randomised clinical trial of selinexor [KPT 330] in patients with diffuse large B-cell lymphoma
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2014
Price : $35 *
At a glance
- Drugs Selinexor (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- 10 Nov 2014 Planned initiation date changed from 1 Aug 2014 to 1 Dec 2014, according to a Karyopharm Therapeutics media release.
- 07 May 2014 Trial initiation is expected in the second half of 2014, according to a Karyopharm Therapeutics media release.
- 10 Mar 2014 New trial record